DNA methylation of immune checkpoints in the peripheral blood of breast and colorectal cancer patients

References

• Jacobs J, Smits E, Lardon F, Pauwels P, Deschoolmeester V. Immune checkpoint modulation in colorectal cancer: what’s new and what to expect. J Immunol Res. 2015;2015:158038. doi:10.1155/2015/158038.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30. doi:10.3322/caac.21387.
   PubMed Web of Science ®Google Scholar
• Wu Y, Sarkissyan M, Vadgama JV. Epigenetics in breast and prostate cancer. Methods Mol Biol. 2015;1238:425–466. doi:10.1007/978-1-4939-1804-1_23.
   PubMedGoogle Scholar
• Chaudhary B, Elkord E. Regulatory T Cells in the tumor microenvironment and cancer progression: role and therapeutic targeting. Vaccines (Basel). 2016;4(3).
   Web of Science ®Google Scholar
• Passardi A, Canale M, Valgiusti M, Ulivi P. Immune checkpoints as a target for colorectal cancer treatment. Int J Mol Sci. 2017;18:1324. doi:10.3390/ijms18061324.
   Web of Science ®Google Scholar
• Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells. Immunol Cell Biol. 2018;96:21–33. doi:10.1111/imcb.1003.
   PubMed Web of Science ®Google Scholar
• Jin HT, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol. 2011;350:17–37. doi:10.1007/82_2010_116.
   PubMed Web of Science ®Google Scholar
• Shi T, Ma Y, Yu L, Jiang J, Shen S, Hou Y, Wang E. Cancer immunotherapy: a focus on the regulation of immune checkpoints. Int J Mol Sci. 2018;19(5).
   Web of Science ®Google Scholar
• Lines JL, Pantazi E, Mak J, Sempere LF, Wang L, O’Connell S, Ceeraz S, Suriawinata AA, Yan S, Ernstoff MS, et al. VISTA is an immune checkpoint molecule for human T cells. Cancer Res. 2014;74:1924–1932. doi:10.1158/0008-5472.CAN-13-1504.
   PubMed Web of Science ®Google Scholar
• Jin B, Robertson KD. DNA methyltransferases, DNA damage repair, and cancer. Adv Exp Med Biol. 2013;754:3–29. doi:10.1007/978-1-4419-9967-2_1.
   PubMed Web of Science ®Google Scholar
• Rasmussen KD, Helin K. Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev. 2016;30:733–750. doi:10.1101/gad.276568.115.
   PubMed Web of Science ®Google Scholar
• Sasidharan Nair V, El Salhat H, Taha RZ, John A, Ali BR, Elkord E. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer. Clinical Epigenetics. 2018;10:78. doi:10.1186/s13148-018-0512-1.
   PubMed Web of Science ®Google Scholar
• Sasidharan Nair V, Toor SM, Taha RZ, Shaath H, Elkord E. DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer. Clin Epigenetics. 2018;10:104. doi:10.1186/s13148-018-0539-3.
   PubMed Web of Science ®Google Scholar
• Solinas C, Gombos A, Latifyan S, Piccart-Gebhart M, Kok M, Buisseret L. Targeting immune checkpoints in breast cancer: an update of early results. ESMO Open. 2017;2:e000255. doi:10.1136/esmoopen-2017-000255.
   PubMed Web of Science ®Google Scholar
• Waki K, Yamada T, Yoshiyama K, Terazaki Y, Sakamoto S, Matsueda S, Komatsu N, Sugawara S, Takamori S, Itoh K, et al. PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer. Cancer Sci. 2014;105:1229–1235. doi:10.1111/cas.12502.
   PubMed Web of Science ®Google Scholar
• Xie J, Wang J, Cheng S, Zheng L, Ji F, Yang L, Zhang Y, Ji H. Expression of immune checkpoints in T cells of esophageal cancer patients. Oncotarget. 2016;7:63669–63678. doi:10.18632/oncotarget.11611.
   PubMedGoogle Scholar
• Arrieta O, Montes-Servin E, Hernandez-Martinez JM, Cardona AF, Casas-Ruiz E, Crispin JC, Motola D, Flores-Estrada D, Barrera L. Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients. Oncotarget. 2017;8:101994–102005. doi:10.18632/oncotarget.22025.
   PubMedGoogle Scholar
• Kim HR, Ha S-J, Hong MH, Heo SJ, Koh YW, Choi EC, Kim EK, Pyo KH, Jung I, Seo D, et al. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. Sci Rep. 2016;6:36956. doi:10.1038/srep36956.
   PubMed Web of Science ®Google Scholar
• Syed Khaja AS, Toor SM, El Salhat H, Faour I, Ul Haq N, Ali BR, Elkord E. Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment. Oncotarget. 2017;8:33159–33171. doi:10.18632/oncotarget.16565.
   PubMed Web of Science ®Google Scholar
• Wang W, Shen G, Wu S, Song S, Ni Y, Suo Z, Meng X, Li D, Zhou L, Hao R, et al. PD-1 mRNA expression in peripheral blood cells and its modulation characteristics in cancer patients. Oncotarget. 2017;8:50782–50791. doi:10.18632/oncotarget.15006.
   PubMedGoogle Scholar
• Syed Khaja AS, Toor SM, El Salhat H, Ali BR, Elkord E. Intratumoral FoxP3(+)Helios(+) Regulatory T Cells upregulating immunosuppressive molecules are expanded in human colorectal cancer. Front Immunol. 2017;8:619. doi:10.3389/fimmu.2017.00619.
   PubMed Web of Science ®Google Scholar
• Dunn J, Rao S. Epigenetics and immunotherapy: the current state of play. Mol Immunol. 2017;87:227–239. doi:10.1016/j.molimm.2017.04.012.
   PubMed Web of Science ®Google Scholar
• Sasidharan Nair V, Toor SM, Ali BR, Elkord E. Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells. Expert Opin Ther Targets. 2018;22:547–557. doi:10.1080/14728222.2018.1471137.
   PubMed Web of Science ®Google Scholar
• Kawaguchi K, Suzuki E, Yamaguchi A, Yamamoto M, Morita S, Toi M. Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer. Breast Cancer. 2017;24:111–120. doi:10.1007/s12282-016-0682-7.
   PubMed Web of Science ®Google Scholar
• Mazel M, Jacot W, Pantel K, Bartkowiak K, Topart D, Cayrefourcq L, Rossille D, Maudelonde T, Fest T, Alix-Panabières C. Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol. 2015;9:1773–1782. doi:10.1016/j.molonc.2015.05.009.
   PubMed Web of Science ®Google Scholar
• Joller N, Hafler JP, Brynedal B, Kassam N, Spoerl S, Levin SD, Sharpe AH, Kuchroo VK. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol. 2011;186:1338–1342. doi:10.4049/jimmunol.1003081.
   PubMed Web of Science ®Google Scholar
• Joller N, Lozano E, Burkett PR, Patel B, Xiao S, Zhu C, Xia J, Tan TG, Sefik E, Yajnik V, et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity. 2014;40:569–581. doi:10.1016/j.immuni.2014.02.012.
   PubMed Web of Science ®Google Scholar
• Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A, Levine Z, Beiman M, Dassa L, Achdout H, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A. 2009;106:17858–17863. doi:10.1073/pnas.0903474106.
   PubMed Web of Science ®Google Scholar
• Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y, Park S, Javinal V, Chiu H, Irving B, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell. 2014;26:923–937. doi:10.1016/j.ccell.2014.10.018.
   PubMed Web of Science ®Google Scholar